Literature DB >> 21518957

ck2-dependent phosphorylation of progesterone receptors (PR) on Ser81 regulates PR-B isoform-specific target gene expression in breast cancer cells.

Christy R Hagan1, Tarah M Regan, Gwen E Dressing, Carol A Lange.   

Abstract

Progesterone receptors (PR) are critical mediators of mammary gland development and contribute to breast cancer progression. Progestin-induced rapid activation of cytoplasmic protein kinases leads to selective regulation of growth-promoting genes by phospho-PR species. Herein, we show that phosphorylation of PR Ser81 is ck2 dependent and progestin regulated in intact cells but also occurs in the absence of PR ligands when cells enter the G(1)/S phase of the cell cycle. T47D breast cancer cells stably expressing a PR-B mutant receptor that cannot be phosphorylated at Ser79/81 (S79/81A) formed fewer soft agar colonies. Regulation of selected genes by PR-B, but not PR-A, also required Ser79/81 phosphorylation for basal and/or progestin-regulated (BIRC3, HSD11β2, and HbEGF) expression. Additionally, wild-type (wt) PR-B, but not S79/81A mutant PR, was robustly recruited to a progesterone response element (PRE)-containing transcriptional enhancer region of BIRC3; abundant ck2 also associated with this region in cells expressing wt but not S79/81A PR. We conclude that phospho-Ser81 PR provides a platform for ck2 recruitment and regulation of selected PR-B target genes. Understanding how ligand-independent PRs function in the context of high levels of kinase activities characteristic of breast cancer is critical to understanding the basis of tumor-specific changes in gene expression and will speed the development of highly selective treatments.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21518957      PMCID: PMC3133426          DOI: 10.1128/MCB.01246-10

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  81 in total

1.  Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells.

Authors:  Jennifer K Richer; Britta M Jacobsen; Nicole G Manning; M Greg Abel; Douglas M Wolf; Kathryn B Horwitz
Journal:  J Biol Chem       Date:  2001-11-20       Impact factor: 5.157

2.  Epidermal growth factor-related peptides activate distinct subsets of ErbB receptors and differ in their biological activities.

Authors:  R R Beerli; N E Hynes
Journal:  J Biol Chem       Date:  1996-03-15       Impact factor: 5.157

3.  Loss of co-ordinate expression of progesterone receptors A and B is an early event in breast carcinogenesis.

Authors:  P A Mote; S Bartow; N Tran; C L Clarke
Journal:  Breast Cancer Res Treat       Date:  2002-03       Impact factor: 4.872

4.  Functional interaction of protein kinase CK2 and c-Myc in lymphomagenesis.

Authors:  Padmalatha Channavajhala; David C Seldin
Journal:  Oncogene       Date:  2002-08-08       Impact factor: 9.867

5.  Persistent nuclear accumulation of protein kinase CK2 during the G1-phase of the cell cycle does not depend on the ERK1/2 pathway but requires active protein synthesis.

Authors:  Francesc A Miro; Franc Llorens; Nerea Roher; Maria Plana; Néstor Gómez; Emilio Itarte
Journal:  Arch Biochem Biophys       Date:  2002-10-15       Impact factor: 4.013

6.  Defective mammary gland morphogenesis in mice lacking the progesterone receptor B isoform.

Authors:  Biserka Mulac-Jericevic; John P Lydon; Francesco J DeMayo; Orla M Conneely
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-01       Impact factor: 11.205

7.  The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins.

Authors:  M Rothe; M G Pan; W J Henzel; T M Ayres; D V Goeddel
Journal:  Cell       Date:  1995-12-29       Impact factor: 41.582

8.  Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes.

Authors:  P Liston; N Roy; K Tamai; C Lefebvre; S Baird; G Cherton-Horvat; R Farahani; M McLean; J E Ikeda; A MacKenzie; R G Korneluk
Journal:  Nature       Date:  1996-01-25       Impact factor: 49.962

9.  Breast cancer and hormone-replacement therapy in the Million Women Study.

Authors:  Valerie Beral
Journal:  Lancet       Date:  2003-08-09       Impact factor: 79.321

10.  Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial.

Authors:  Rowan T Chlebowski; Susan L Hendrix; Robert D Langer; Marcia L Stefanick; Margery Gass; Dorothy Lane; Rebecca J Rodabough; Mary Ann Gilligan; Michele G Cyr; Cynthia A Thomson; Janardan Khandekar; Helen Petrovitch; Anne McTiernan
Journal:  JAMA       Date:  2003-06-25       Impact factor: 56.272

View more
  44 in total

1.  Progesterone Receptor Attenuates STAT1-Mediated IFN Signaling in Breast Cancer.

Authors:  Merit L Goodman; Gloria M Trinca; Katherine R Walter; Evangelia K Papachristou; Clive S D'Santos; Tianbao Li; Qi Liu; Zhao Lai; Prabhakar Chalise; Rashna Madan; Fang Fan; Mary A Markiewicz; Victor X Jin; Jason S Carroll; Christy R Hagan
Journal:  J Immunol       Date:  2019-04-01       Impact factor: 5.422

2.  Testosterone signaling and the regulation of spermatogenesis.

Authors:  William H Walker
Journal:  Spermatogenesis       Date:  2011-04

Review 3.  Progesterone action in breast, uterine, and ovarian cancers.

Authors:  Caroline H Diep; Andrea R Daniel; Laura J Mauro; Todd P Knutson; Carol A Lange
Journal:  J Mol Endocrinol       Date:  2015-01-13       Impact factor: 5.098

Review 4.  Progesterone receptors (PR) mediate STAT actions: PR and prolactin receptor signaling crosstalk in breast cancer models.

Authors:  Katherine A Leehy; Thu H Truong; Laura J Mauro; Carol A Lange
Journal:  J Steroid Biochem Mol Biol       Date:  2017-04-23       Impact factor: 4.292

Review 5.  Role of phosphorylation in progesterone receptor signaling and specificity.

Authors:  Christy R Hagan; Andrea R Daniel; Gwen E Dressing; Carol A Lange
Journal:  Mol Cell Endocrinol       Date:  2011-09-16       Impact factor: 4.102

Review 6.  Extranuclear signaling by sex steroid receptors and clinical implications in breast cancer.

Authors:  Viroj Boonyaratanakornkit; Nalo Hamilton; Diana C Márquez-Garbán; Prangwan Pateetin; Eileen M McGowan; Richard J Pietras
Journal:  Mol Cell Endocrinol       Date:  2017-11-14       Impact factor: 4.102

7.  Progesterone receptor-cyclin D1 complexes induce cell cycle-dependent transcriptional programs in breast cancer cells.

Authors:  Gwen E Dressing; Todd P Knutson; Matthew J Schiewer; Andrea R Daniel; Christy R Hagan; Caroline H Diep; Karen E Knudsen; Carol A Lange
Journal:  Mol Endocrinol       Date:  2014-02-25

8.  Active FOXO1 Is a Key Determinant of Isoform-Specific Progesterone Receptor Transactivation and Senescence Programming.

Authors:  Caroline H Diep; Todd P Knutson; Carol A Lange
Journal:  Mol Cancer Res       Date:  2015-11-17       Impact factor: 5.852

9.  Differential Regulation of Progesterone Receptor-Mediated Transcription by CDK2 and DNA-PK.

Authors:  Lindsey S Treviño; Michael J Bolt; Sandra L Grimm; Dean P Edwards; Michael A Mancini; Nancy L Weigel
Journal:  Mol Endocrinol       Date:  2015-12-11

Review 10.  Tracking progesterone receptor-mediated actions in breast cancer.

Authors:  Todd P Knutson; Carol A Lange
Journal:  Pharmacol Ther       Date:  2013-11-26       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.